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Abstract
The Notch signaling pathway and the delta-like 4 ligand (DLL4)
play key roles in embryonic vascular development. Many of the
pathways involved in embryonic vascular development also
play important roles in tumor angiogenesis. In this study, we
assessed the expression of DLL4 in primary renal cancer and
investigated the biological function of DLL4 in primary
endothelial cells. Using real-time quantitative PCR and in situ
hybridization, we showed that the expression of DLL4 was up-
regulated within the vasculature of clear cell-renal cell
carcinoma almost 9-fold more than normal kidney and was
correlated with the expression of vascular endothelial growth
factor (VEGF). The expression of DLL4 in endothelial cells was
up-regulated by VEGF and basic fibroblast growth factor
synergistically, and by hypoxia through hypoxia-inducible
factor 1A. Down-regulation of DLL4 expression with RNA
interference led to decreased expression of HEY1 and
EphrinB2, and the inhibition of endothelial cell proliferation,
migration, and network formation, all of which are important
processes in tumor angiogenesis. The inhibition of prolifera-
tion occurred via the induction of cell cycle arrest in G0-G1 by
increased expression of p21 and decreased phosphorylation of
retinoblastoma. We conclude that an optimal window of the
DLL4 expression is essential for tumor angiogenesis and that
selective modulation of the DLL4 expression within human
tumors may represent a potential novel antiangiogenic
therapy. (Cancer Res 2005; 65(19): 8690-7)
Introduction
Tumor angiogenesis is an important process in tumor growth
and metastatic progression (1). Many solid tumors are known to
develop hypoxic microenvironments as a result of insufficient or
aberrant blood supplies. Activation of the hypoxia-inducible factors
HIF-1a and HIF-2a in response to hypoxia leads to the up-
regulation of numerous adaptive proteins, including angiogenic
factors such as vascular endothelial growth factor (VEGF; ref. 2).
Many of the processes involved in tumor angiogenesis are
mirrored during embryonic vascular development. In the past
decade, the Notch signaling pathway has been shown to play a key
role in vascular development. The Notch pathway is an evolutionary
conserved intercellular signaling pathway involved in numerous
biological processes including cell fate determination, cellular
differentiation, proliferation, survival, and apoptosis (3–5). In
mammalian cells, there are five transmembrane Notch ligands
[Jagged1, Jagged2, delta-like 1 ligand (DLL1), DLL3, and DLL4] and
four Notch receptors (Notch1-4). Ligand-receptor binding activates
the signaling pathway by initiating the cleavage of the Notch
intracellular domain from the cell membrane (6, 7). The Notch
intracellular domain subsequently translocates to the nucleus where
it classically interacts with the transcription factor C promoter
binding factor 1 (CBF1)/recombination signal binding protein Jn
(RBP-Jn)/Suppressor of Hairless [Su(H)]/Lag-1 protein (CSL). The
basic helix-loop-helix-orange proteins (bHLH) Hairy/Enhancer of
Split (HES1, 5, and 7) and the HES-related proteins (HEY1, HEY2, and
HEYL) are the best-characterized downstream targets of the Notch
intracellular domain/CSL complex (8–10).
Mice deficient for various Notch components die in utero of
severe vascular abnormalities (11). DLL4 knockout mice display
vascular defects similar in pattern to those seen in Notch1/Notch4
double knockouts. Interestingly, haploinsufficiency of DLL4 also
results in embryonic lethality from severe vascular defects (12–14).
Haploinsufficiency for angiogenic factors is uncommon and high-
lights the importance of DLL4 over and above other components of
the Notch pathway. Similar phenotypes have been only described
for VEGF knockout mice (15, 16).
We and others have previously shown that DLL4 is expressed at
sites of vascular development and angiogenesis (14, 17, 18). During
early embryonic development, DLL4 is initially observed in major
arterial vessels; with embryonic maturation, this pattern of
expression disappears whereupon it is confined to small vessels
and capillaries. DLL4 is up-regulated at sites of physiologic and
pathologic angiogenesis (17). It is high in ovarian vessels
surrounding growing follicles and is up-regulated within the tumor
vasculature when compared with adjacent normal tissues.
Xenograft studies showed high expression of mouse DLL4, but
not of human-derived DLL4, within the tumor vasculature. We have
shown in vitro that DLL4 is a hypoxia-regulated gene, although the
pathway was unknown (17).
In this study, we investigated the expression of DLL4 in renal
tumors, analyzed the relationship between DLL4, hypoxia, and
angiogenic growth factors, and assessed the biological function of
DLL4 in tumor angiogenesis.
Materials and Methods
Cells and tissue samples. Human umbilical vein endothelial cells
(HUVEC) were isolated from fresh human umbilical cords by infusion with
0.1% collagenase (Sigma-Aldrich, St. Louis, MO). Human aortic endothelial
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cells (HAEC) were obtained from PromoCell (Heidelberg, Germany). Human
iliac artery endothelial cells (HIAEC) and human femoral artery endothelial
cells (HFAEC) were purchased from LGC Promochem (London, United
Kingdom). Endo742, a gift from Mike O’Hare (University College London,
London, United Kingdom), is an immortalized normal human breast
endothelial cell line (19). All tissue cultures were done using MCDB131
medium containing HEPES (4.8 g/L), 20% heat inactivated FCS, 50 Ag/mL
endothelial cell growth supplement (ECGS), 5 IU/mL heparin, 100 IU/mL
penicillin, 100 Ag/mL streptomycin, and 2 mmol/L glutamine (Sigma-
Aldrich). Cells were incubated at 37jC in a humidified atmosphere of 5%
CO2. Cells exposed to hypoxia were incubated for 16 hours at 0.1% O2 and
5% CO2. Cells were not used beyond passage 6. Human tissue samples were
obtained postoperatively from the Department of Urology, Churchill
Hospital (Oxford, United Kingdom). All patients gave signed, informed
consent for their tissues to be used for scientific research. Areas of normal
tissue and tumor were identified by Dr. D.R. Davies (Consultant Pathologist,
John Radcliffe Hospital, Oxford, United Kingdom).
RNA interference. Chemically synthesized gene-specific small interfering
RNA (siRNA) duplexes were designed, BLASTsearched, andmanufactured by
Eurogentec (Seraing, Belgium) as per accepted guidelines (20). The following
siRNA sequences were used: DLL4-Duplex1 (20 nmol/L): CUACUAUGGAGA-
CAACUGCTT; DLL4-Duplex2 (20 nmol/L): UGACCACUUCGGCCACUAUTT;
DLL4 scrambled control (20 nmol/L): UCUGAAAAGCACGCUUGACTT; HIF-
1a (50 nmol/L): CUGAUGACCAGCAACUUGATT; HIF-2a (50 nmol/L):
CAGCAUCUUUGAUAGCAGUTT; and HIF scrambled control (50 nmol/L):
AGUUCAACGACCAGUAGUCTT. Transfection of siRNA duplexes was done
with cells at 40% to 50% confluency using 3 mL of Optimem-1 and 12 AL of
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Biological functional assays
and gene expression analysis were done 24 hours after siRNA transfection.
RNA extraction and reverse transcription. Extraction of total RNA
from cultured endothelial cells was done using TRI-Reagent (Sigma-Aldrich)
as per instructions of the manufacturer. The quality of RNA extracted was
assessed using RNA 6000 Nano Chips and the Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA). cDNA was synthesized by reverse
transcribing total RNA with the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA).
Real-time quantitative PCR. Real-time quantitative PCR reactions were
done in triplicate using the Corbett Research Rotor Gene RG-3000 (Sydney,
Australia). Each reaction was done in an individual tube and made to 25 AL
containing the equivalent of 5 ng reverse-transcribed RNA (1 ng in the case
of 18S rRNA), 12.5 AL TaqMan 2 PCR Master Mix (Applied Biosystems),
and 1.25 AL the probe/primer mix. Human h-actin (renal samples) and
eukaryotic 18S rRNA (endothelial cells) were used as reference genes to
normalize for differences in the amount of total RNA in each sample. The
following primer/probe kits were purchased as Assays-on-Demand from
Applied Biosystems: DLL4 (Hs00184092_m1), HES1 (Hs00172878_m1), HEY1
(Hs00172878_m1), HEY2 (Hs00232622_m1), Ephrin B2 (Hs00187950_m1),
VEGFR2 (Hs00176676_m1), CD34 (Hs00156373_m1), and VEGF
(Hs00173626_m1). The reaction efficiency for each gene was calculated
after obtaining standard curves for each PCR reaction by making 2-fold
serial dilutions covering the range equivalent to 20 to 0.625 ng RNA (5-0.125
ng for 18S rRNA). Relative quantitation of gene expression was done using
the method described by Pfaffl (21). The relative ratio of gene expression
was calculated as [(Etarget)DCtTARGET(mean comparator  mean sample)] 
[(Eref)DCtREF(mean comparator  mean sample)], where Etarget is reaction
efficiency of the gene of interest; Eref, reaction efficiency of the reference
gene; and DCt, the cycle difference between the comparator and the sample.
All calculations are based on the mean value of PCR reactions done in
triplicate. The comparator for the clinical samples was the median normal
kidney; the comparator for cell line work is stated accordingly in the figure
legends.
Reverse transcription-PCR. Standard PCR reactions were done using
HotStarTaq DNA polymerase (Qiagen, Valencia, CA). In brief, 2
HotStarTaq master mix was combined with 1 Amol/L primers and 5 ng
cDNA in a total volume of 20 AL. PCR cycling was done for 38 cycles. PCR
products were separated on 1.7% agarose gels stained with ethidium bro-
mide. The following primer sequences were used:
In vitro angiogenesis assays. In vitro angiogenesis assays included
endothelial cell proliferation, network formation, migration, and scratch
wound closure. For the cell proliferation assays, 3  104 HUVECs were
seeded in triplicate 24 hours posttransfection into 24-well plates precoated
with 0.2% gelatin and grown in 0.5 mL culture medium. After 24 hours,
medium was removed, cells washed with PBS, trypsinized, and counted
using a Beckman Z2 Coulter counter (Fullerton, CA; ref. 22). Thymidine
incorporation assay (23) was done by seeding 2  103 HUVECs in triplicate,
24 hours posttransfection in 96-well plates. After 24 hours, 1 Ci/mL (1 Ci =
37 kBq) of [methyl-3H]thymidine (Amersham Biosciences, Chalfont St. Giles,
United Kingdom) was added to each well and incubated for 16 hours.
Thymidine incorporation was assessed using a Wallac 1450 microbeta liquid
scintillation counter.
For the matrigel network formation assay, each well of a 24-well Falcon
tissue culture plate was evenly coated with 250 AL Matrigel (BD Biosciences,
Bedford, MA). 4  104 HUVECs were seeded 24 hours posttransfection in
triplicate per well in MCDB131 + 20% FCS + ECGS. Network formation was
assessed after 16 hours by photographing the matrices using a Zeiss Axiovet
135 inverted light microscope and a Nikon CoolPix 4500 digital camera.
Quantification of tube formation was done using Adobe Photoshop 7.0.
For the cell migration assays, following transfection and quiescing for
24 hours, 5  104 cells were seeded in triplicate in MCBD131 + 1% FCS into
the insert well of the BD BioCoat Endothelial Cell Migration Assay plate (BD
Biosciences; ref. 24). Migration across the microporous membrane occurred
in response to stimuli within the lower chamber (MCDB131 + 5% FCS,
MCBD131 + 1% FCS + 10 ng/mL VEGF165; R&D Systems, Minneapolis, MN).
Following a 22-hour incubation, the cells were labeled with Calcein AM
(Molecular Probes, Eugene, OR) and the fluorescent signal from the
Gene Forward primer
sequence
Reverse primer
sequence
Size (bp)
Notch1 CAGGCAATCCG
AGGACTATG
CAGGCGTGTTG
TTCTCACAG
428
Notch2 CACTGGGTCGA
TGATGAAGG
ATCTGGAAGAC
ACCTTGGGC
515
Notch3 TCTTGCTGCTG
GTCATTCTC
TGCCTCATCCT
CTTCAGTTG
485
Notch4 CACTGAGCCAA
GGCATAGAC
ATCTCCACCTC
ACACCACTG
471
Jagged1 TCGCTGTATCT
GTCCACCTG
AGTCACTGGCA
CGGTTGTAG
227
Jagged2 GATTGGCGGCT
ATTACTGTG
AGGCAGTCGTC
AATGTTCTC
600
DLL1 AGAAAGTGTGC
AACCCTGGC
GCTCCCTCCGT
TCTTACAAG
401
DLL3 GTGAATGCCGA
TGCCTAGAG
GGTCCATCTGC
ACATGTCAC
256
DLL4 TGACCACTTCG
GCCACTATG
AGTTGGAGCCG
GTGAAGTTG
620
HES1 TGGATGCGGAG
TCTACGATG
TAAGGCCACTT
GCCACCTTC
468
HES5 GAAAAACCGAC
TGCGGAAGC
GGAAGTGGTAC
AGCAGCTTC
314
HES7 TCGAGCTGAGA
ATAGGGACG
GAAACCGGACA
AGTAGCAGC
274
HEY1 GCCAGCATGA
AGCGAGCTC
GGGTCAGAGGC
ATCTAGTCC
453
HEY2 AGATGCTTCAG
GCAACAGGG
CTGAATCCGCA
TGGGCAAAC
408
HEYL AGAAAGCCGAG
GTCTTGCAG
GTAAGCAGGAG
AGGAGACAC
389
h-actin CATCACCATTG
GCAATGAGC
CGATCCACACG
GAGTACTTG
284
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undersurface of the membrane measured using a BMG FLUOstar
fluorescence plate reader. Images of the insert well were captured using a
Zeiss Axiovet 135 inverted light microscope and an Axiocam digital camera.
Scratch wound assay was done as described (25). Twenty-four hours after
transfection, 4  105 HUVECs were seeded in triplicate into a six-well
Falcon tissue culture plate. Cells were fluorescently labeled with 5 Amol/L
CMFDA CellTracker dye (Molecular Probes); after which, the monolayer
was ‘‘scratched’’ and incubated in MCDB131 + 10% FCS + 50 ng/mL VEGF +
2.5 Ag/mL Mitomycin C (Sigma-Aldrich). The wounded area was photo-
graphed using a Zeiss Axiovet 135 inverted light microscope and a Nikon
CoolPix 4500 digital camera. Quantitation of wound width was done using
Adobe Photoshop 7.0.
Cell cycle analysis. Twenty-four hours after transfection, synchroniza-
tion of cell cycles was achieved by culturing HUVECs for 24 hours in
MCDB131 + 2% FCS. Cells were subsequently cultured for 24 hours in either
MCDB131 + 20% FCS + ECGS or MCDB131 + 2% FCS, and then fixed in 70%
ethanol. Cell cycle analysis was done by fluorescence-activated cell sorting
analysis after pretreating cells with RNase (100 Ag/mL) and staining nuclear
DNA with propidium iodide (50 Ag/mL, Sigma-Aldrich; ref. 23).
Apoptosis analysis. 1  105 HUVECs were seeded in triplicate in
MCDB131 + 20% FCS + ECGS into a 24-well Falcon tissue culture plate. After
24 hours, the cells were serum and growth factor deprived using MCDB131
+ 1% FCS. Cell viability was assessed by periodically counting the number of
adherent cells using the Beckman Z2 Coulter counter. Apoptosis was
assessed using the Apo-ONE Homogenous Caspase 3/7 Assay (Promega
Corp., Madison, WI; ref. 26). 2  104 HUVECs were seeded in triplicate in
100 AL MCDB131 + 20% FCS + ECGS with 100 AL Apo-ONE reagent in a
96-well white-walled tissue culture plate. After 4 hours, fluorescence was
measured at 485/530 nm using a Bio-Tek Flx800 fluorescence plate reader.
In situ hybridization. Radioactive in situ hybridization on paraffin-
embedded sections was done by the in situ hybridization service, Cancer
Research UK (London), using a method we described previously (17). The
probe used in the in situ hybridization for DLL4 was a 741 bp fragment
located from position 1,775 to 2,516 bp (17).
Western blotting. Protein extraction and Western blotting were done as
previously described (27). Antibodies against the following proteins were
used for detection: HIF-1a (1:1,000; BD PharMingen, San Diego, CA), HIF-2a
(1:1,000; Abcam, Cambridge, MA), p21 (1:100; Calbiochem, San Diego, CA),
p27 (1:500; Cell Signaling), retinoblastoma (1:500; BD PharMingen, Bedford,
MA), and h-tubulin (1:10,000; Sigma-Aldrich).
Immunohistochemistry. Immunohistochemistry was done as previous-
ly described (28). In brief, paraffin-embedded sections were dewaxed,
rehydrated, and incubated with the anti-CD34 monoclonal antibody QBEnd
10 (Novocastra, Newcastle, United Kingdom). Visualization was achieved
using the EnVision HRP kit (DAKO Cytomation, Carpinteria, CA).
Statistics. Statistical analysis was done using GraphPad Prism. Statistical
tests used included t test, one-way ANOVA, Mann-Witney, and Spearman’s
rank correlation coefficient. Statistical significance was taken at a P value of
<0.05 and is denoted in the figures with an asterisk.
Results
DLL4 expression in renal cancer. In situ hybridization was used
to study the expression pattern of DLL4 within the vasculature of
normal kidney and clear cell-renal cell carcinoma (CC-RCC). Blood
vessels were identified by immunostaining for the pan-endothelial
marker CD34, which stained only blood vessels. In comparison
with CD34, the expression of DLL4 was up-regulated in the tumor
endothelium but not in the normal renal vasculature (Fig. 1A).
Using quantitative PCR, the expression of DLL4 in 25 CC-RCCs
and 7 non–clear cell tumors [5 papillary renal cell carcinomas,
2 transitional cell carcinomas] was compared with 11 normal
kidneys. The expression of DLL4 in CC-RCCs (85.0 F 99) was
almost 9 times higher than in normal kidneys (9.6 F 8.4, P < 0.001)
and 20 times higher than in non–clear cell tumors (4.3 F 6.7, P <
0.001; Fig. 1B). The relative vascularity of the tissues was assessed
by measuring the expression of CD34. The expression of DLL4 was
quantified in relation to CD34 (DLL4/CD34 ratio = relative
expression of DLL4/relative expression of CD34). Renal tumors
showed increased vascularity as revealed by the expression of
CD34 compared with normal kidneys; tumor samples, however,
also displayed a significantly higher ratio of DLL4 to CD34 than
normal kidneys (P < 0.01; data not shown). The expression of DLL4
in HUVECs was 40 times higher than in normal kidneys and was
similar to the level in tumors (DLL4/CD34 ratio = 38). We have
previously shown that microvessel density and the protein level of
VEGF are higher in CC-RCCs than in non–clear cell tumors and
normal kidneys (28). Using quantitative PCR, we showed that the
RNA level of VEGF was also significantly higher in CC-RCCs than in
normal tissues and other tumor types (P < 0.001; data not shown).
Comparison of the expressions of DLL4 and VEGF in CC-RCCs
showed that the expression of DLL4 is significantly associated with
high levels of VEGF. The Spearman rank correlation coefficient for
CC-RCC was 0.75 (P < 0.0001; Fig. 1C).
Regulation of DLL4 by hypoxia and angiogenic growth
factors. Quantitative PCR was used to study DLL4 expression in
five endothelial cell lines, including HUVEC, HAEC, HIAEC,
HFAEC, and Endo742, cultured at subconfluence in MCDB131 +
20% FCS + ECGS. The expression of DLL4 was highest in HFAEC,
Figure 1. Expression of DLL4 in renal cancer. A, the expression pattern of DLL4
was studied using in situ hybridization and compared with the endothelial marker
CD34, assessed by immunochemistry. DLL4 signal was undetectable in
normal renal tissue (magnification, 200); however, a number of vessels within
the vasculature of a CC-RCC showed high levels of expression (magnification,
500). One of the vessels was marked with a dot line. B, quantitative PCR
was used to assess the expression of DLL4 in renal tissues (comparator: median
normal kidney). DLL4 expression was significantly higher in CC-RCC compared
with non–clear cell tumors (P < 0.001) and normal renal tissue (P < 0.001).
C, there was a positive correlation between VEGF and DLL4 expression in the
CC-RCCs (Spearman rank correlation coefficient = 0.75, P < 0.0001, n = 25).
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with similar expression in HIAEC and HUVEC. DLL4 expression
was lowest in HAEC and Endo742 (Fig. 2A). DLL4 was up-
regulated by hypoxia in all these cell lines. Cells with high basal
expression (HUVEC, HIAEC, and HFAEC) showed a 2- to 3-fold
induction whereas those with low basal expression showed a 6- to
7-fold increase in DLL4 expression (Fig. 2B). HIF-1a and HIF-2a
in HUVEC were selectively silenced using siRNA (27). Hypoxic
up-regulation of the DLL4 expression was preserved in the mock
transfection, scrambled control, and HIF-2a groups, but dis-
appeared in the HIF-1a group, indicating that DLL4 is a HIF-1–
regulated gene (Fig. 2C).
The regulation of DLL4 expression by various angiogenic growth
factors was also assessed. HUVECs were first quiesced for 24 hours
in MCBD131 + 2% FCS and then were cultured for 24 hours in
MCDB131 + 2% FCS F growth factor. 100 ng/mL VEGF165 and
10 ng/mL basic fibroblast growth factor (bFGF; ref. 29) increased
DLL4 expression 2.5- to 3-fold (P < 0.05) whereas a combination
of the two increased expression 6-fold (P < 0.001). However,
hepatocyte growth factor (20 ng/mL) and macrophage chemo-
attractant protein-1 (20 ng/mL) did not influence DLL4 expression
(Fig. 2D).
The effects of silencing DLL4 using small interfering RNA.
Reverse transcription-PCR (RT-PCR) was used to determine which
key components of the Notch pathway were expressed by endo-
thelial cells. HUVECs express all four Notch receptors (Notch1-4),
four ligands (Jagged1, Jagged2, DLL1, and DLL4), HES1, HEY1, HEY2,
and HES7 (weak), but not DLL3, HES5, or HEYL (Fig. 3A). Two
different siRNA duplexes specific for DLL4 were used to modulate
the expression of DLL4 in HUVECs; DLL4 knockdown was evident
up to 4 days posttransfection.
Quantitative PCR was then used to further assess the effects of
silencing basal DLL4 on key downstream genes including the
previously identified bHLH proteins, VEGFR2, and EphrinB2. Down-
regulating DLL4 by 80% led to a 60% decrease in HEY1 expression
(P < 0.01) and a 40% decrease in EphrinB2 expression (P < 0.05).
There was no significant change in the expression levels of HES1,
HEY2, or VEGFR2 following DLL4 RNA interference (RNAi; Fig. 3B).
The effect of DLL4 silencing on endothelial cell proliferation.
The proliferation of HUVECs transfected with siRNA duplexes
specific for DLL4 (Duplex1 and Duplex2) was significantly inhibited
compared with mock transfection and scrambled control (P < 0.001;
Fig. 4A). This effect was also shown in Endo742 (data not shown), but
not in RT112 (Fig. 4B), a transitional cell carcinoma cell line which
does not express DLL4. The inhibition of proliferation was further
confirmed using a [3H]thymidine uptake assay (data not shown).
Figure 3. Expression of Notch pathway components in HUVECs and the
analysis of the expression of DLL4 and downstream genes following RNAi.
A, RT-PCR was used to analyze the expression of a variety of Notch
components in HUVECs. B, quantitative PCR was used to further assess
changes in the expression levels of some key downstream genes following
transfection of DLL4 Duplex1 (+) into HUVECs. Results of five separate
experiments. Eighty-percent knockdown of DLL4 was consistently achieved
(P < 0.001). This was associated with significant decreases in the expression of
EphrinB2 (P < 0.05) and HEY1 (P < 0.01). Comparator: Scram ().
Figure 2. DLL4 is regulated by hypoxia, VEGF, and
bFGF. A, the relative expression of DLL4 in HUVECs was
measured using quantitative PCR (comparator: HUVEC).
The basal expression of DLL4 in HUVECs was comparable to
expression levels in arterial endothelial cells (n = 3). B, DLL4
expression was significantly increased in all five cell lines
tested following hypoxic incubation (P < 0.05, n = 3;
comparator: normoxia). C, siRNA duplexes were used to
silence the expression of HIF-1 and HIF-2 in HUVECs.
Down-regulation of HIF-1, but not of HIF-2, blocked the
hypoxic up-regulation of DLL4 in HUVECs (n = 4;
comparator: normoxia). D, DLL4 expression was significantly
up-regulated by VEGF (100 ng/mL) and bFGF (15 ng/mL;
P < 0.05, n = 3); a combination of the two led to a
further increase [P < 0.001, n = 3; comparator: control
(MCDB131 + 2% FCS)]. N, normoxia; H, hypoxia.
DLL4 and Endothelial Cell Function
www.aacrjournals.org 8693 Cancer Res 2005; 65: (19). October 1, 2005
Research. 
on May 9, 2015. © 2005 American Association for Cancercancerres.aacrjournals.org Downloaded from 
DLL4 down-regulation did not induce apoptosis in HUVECs cul-
tured in serum- and growth factor–rich medium (MCDB131 + 20%
FCS + ECGS; data not shown), but led to increased apoptosis of the
cells following serum and growth factor deprivation. The number of
viable cells was significantly (P < 0.01) lower following transfection
with Duplex1 and 2 when compared with mock and scrambled
controls (Fig. 4C). Treatment with Duplex1 and 2 was associated
with a significant increase in caspase-3/-7 activity (Fig. 4D).
Analysis of HUVECs stained with propidium iodide showed that
DLL4 knockdown led to cell cycle arrest in G0-G1 (Fig. 5A). After
serum and growth factor stimulation, 28.3% (F9.3 SE) of cells
transfected with scrambled control were in S phase compared with
2.54% (F0.8 SE) for Duplex1 (P < 0.01) and 10.4% (F3.4 SE) for
Duplex2 (P < 0.05; Fig. 5B). Down-regulation of DLL4 increased
levels of p21 and decreased levels of the phosphorylated
retinoblastoma. No change was noted for the p27 protein (Fig. 5C).
Figure 4. Down-regulation of DLL4 inhibits endothelial cell
proliferation and increases apoptosis following serum
starvation. A, cell count assay showed an inhibition of
proliferation in HUVECs following treatment with two siRNA
duplexes specific for DLL4 (P < 0.001, n = 9). B, no
inhibition of proliferation was shown in the bladder cell line
RT112 (n = 3). C, silencing DLL4 expression in HUVECs
significantly decreased cell survival following serum and
growth factor deprivation in MCBD131 + 1% FCS
(P < 0.01, n = 9). D, the decrease was associated with an
increase in caspase-3/-7 activity in HUVECs treated with
Duplex1 and Duplex2 (P < 0.01, n = 9).
Figure 5. DLL4 knockdown induces cell cycle arrest by increasing
p21 expression and inhibiting retinoblastoma phosphorylation.
A, propidium iodide–based cell cycle analysis was done following
siRNA transfection. Synchronization of cell cycles was achieved by
culturing in MCDB131 + 2% FCS for 24 hours. Subsequently,
cells were cultured for 24 hours in either MCDB131 + 2% FCS
only (Scram Q, Duplex1 Q, and Duplex2 Q) or MCDB131 + 20%
FCS + ECGS (Scram STIM, Duplex1 STIM, and Duplex2 STIM).
HUVECs treated with siRNA specific for DLL4 seem to arrest in
G0-G1 and did not progress through the cell cycle following growth
factor and serum stimulation compared with scrambled control.
B, S-phase analysis showed that 28.36% (F9.3 SE) of Scram
STIM cells were in S phase compared with 2.54% (F0.8 SE) for
Duplex1 (P < 0.01) and 10.41% (F3.4 SE) for Duplex2 (P < 0.01;
n = 3). C, Western blot analysis showed that down-regulation of
DLL4 in HUVECs leads to increased expression of p21 and
decreased phosphorylation of retinoblastoma (n = 3).
Cancer Research
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The effects of modulation of DLL4 expression on endothelial
cell network formation and migration. A reduction in the basal
levels of DLL4 led to decreased network formation in matrigel
(Fig. 6A). Network formation, as judged by total tube length, was
significantly lower (P < 0.001) following treatment with Duplex1
and Duplex2 compared with scrambled control.
BD BioCoat Endothelial Cell Migration plates were used to study
the effects of silencing DLL4 on HUVEC migration. HUVECs in
which DLL4 was silenced were less responsive to VEGF-induced
migration compared with scrambled control (P < 0.01). There was
no difference when FCS alone was used to stimulate migration
(Fig. 6B). Endothelial cell migration was further analyzed using the
scratch wound assay. Down-regulation of DLL4 using siRNA
significantly (P < 0.001) inhibited VEGF-stimulated wound closure
when compared with scrambled control (Fig. 6C).
Discussion
In this study, we described that the expression of DLL4, as
assessed by quantitative PCR, was strikingly up-regulated in CC-
RCCs, consistent with our previous in situ hybridization work on
five renal cancer/normal pairs (17). This is the first quantitative
evaluation of the frequency and extent of DLL4 up-regulation in
cancer. CC-RCC, the most common type of malignant renal tumor,
accounting for 70% to 80% of cases (30), occurs in both a
hereditary and sporadic form, both of which are associated with
mutations in the von Hippel-Lindau (VHL) gene (31, 32).
Although DLL4 was undetectable in adult endothelium in vivo ,
we found, as have others, that several primary endothelial cells do
express it in vitro (29, 33–35). The ratio of DLL4 to CD34 in
HUVECs is similar to that found in the highest expressing CC-
RCCs. We therefore chose HUVEC as a model to investigate the
biological function of DLL4 in tumor angiogenesis. We confirmed
that DLL4 is a hypoxia-regulated gene and proved that the hypoxic
regulation is dependent on HIF-1 rather than HIF-2.
We showed that the expression of DLL4 in HUVECs is up-
regulated by VEGF and bFGF, and their combination leads to a
synergistic further increase in expression. Indeed, the combination
of VEGFand bFGFcan induce DLL4, Notch1, and Notch4 in HUVECs
(29). The regulation of DLL4 by VEGF in vitro and the significant
correlation between DLL4 and VEGF expression in CC-RCCs imply
that VEGFmay act upstream of DLL4 in the tumors. It is noted that
VEGF can act upstream of DLL4 and Notch4 in the determination of
arterial endothelial cell fate in zebra fish (36). bFGF is also produced
by renal cancers (37) through a non-HIF pathway. Thus, the
combination of VEGF and bFGF may contribute to the high
expression of DLL4 within the tumor vasculature.
Using conventional RT-PCR, we showed that HUVECs express all
four Notch receptors, four ligands (Jagged1, Jagged2, DLL1, and
DLL4), and four bHLH transcription factors [HES1, HEY1, HEY2,
and HES7 (weak)], but not DLL3, HES5, and HEYL. Indeed, other
groups (29, 35) have shown that HUVECs express Notch1, Notch4,
and DLL4, whereas there is also a report indicating that HUVECs
express Notch1, 2, 3, and 4 and Jagged1, but not DLL4 (33). The
discrepancy for the expression of Notch receptors and ligands in
HUVECs may reflect cell heterogeneity or variations between cell
batches.
Several groups have attempted to unravel the role of the Notch
pathway in endothelial cell biology via the overexpression of Notch
signaling components (Jagged1, HES1, and HEY1) or the active
Notch intracellular domain of Notch1 and Notch4 (29, 33, 35, 38, 39).
Clearly, there are problems of induced high expression, particularly
Figure 6. Down-regulation of basal DLL4 expression
inhibits endothelial cell network formation and migration.
A, endothelial cell network formation was assessed
using a Matrigel assay. Representative areas were
photographed at 15 magnification and quantified using
Adobe Photoshop. Down-regulation of DLL4 in HUVECs
led to a significant decrease in total tube length
compared with scrambled control (P < 0.001, n = 9).
B, endothelial cell migration was assessed using a BD
BioCoat Migration Plate. Down-regulation of DLL4 inhibits
VEGF (10 ng/mL)–stimulated migration in HUVECs
(P < 0.01, n = 9). No modulation of serum-stimulated
migration was noted. C, HUVEC migration was further
assessed using a scratch wound assay. Wound closure
in response to VEGF stimulation (50 ng/mL) was
significantly reduced following DLL4 knockdown
(P < 0.001, n = 9).
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relating to physiologic significance. Therefore, we assessed the
biological function of DLL4 by using RNAi to reduce its endogenous
expression. Down-regulating DLL4 by 80% led to significant
decreases in the expression levels of EphrinB2 and HEY1, indicating
a basal role of the DLL4 expression in the regulation of these
pathways. HUVECs express several Notch ligands (Jagged1,
Jagged2, DLL1, and DLL4); however, regulation of DLL4 alone had
substantial effects, suggesting that it is one of the main ligands
regulating basal Notch function in endothelial cells. Surprisingly,
we have shown that silencing DLL4 in endothelial cells leads to a
significant inhibition of proliferation, a result previously found for
overexpression studies. The inhibition is due to the arrest of cell
cycle in G0-G1, an effect mediated by an increase in levels of p21
and a decrease in the phosphorylation of retinoblastoma.
The induction of p21 and resultant decreased phosphorylation of
retinoblastoma have previously been shown to induce G0-G1 cell
cycle arrest in HUVECs (40–42). However, overexpression of Notch4
or knockout of Notch1 and Notch4 produces similar phenotypes
(43, 44). Taken together, this suggests that an optimal range of the
Notch signaling is important in the proliferation of endothelial
cells.
The effects on apoptosis were reciprocal. We showed that
silencing DLL4 induces apoptosis in HUVECs, only following
deprivation of serum and growth factors. Overexpression of Notch1,
Notch4, or HES1 protects primary endothelial cells against serum
starvation–induced apoptosis and inhibits lipopolysaccharide-
induced apoptosis (29).
We showed that down-regulation of DLL4 reduces the network
formation of HUVECs on matrigel. Up-regulation of Notch1 or HES1
results in stabilization of network formation, whereas inhibition of
Notch signaling with a dominant-negative CSL partially inhibits
VEGF-driven network formation in HIAECs (29). However, both
overexpression and reduction of HEY1 with antisense oligonucleo-
tides blocked endothelial cell network formation in vitro (45). Using
the trans-well migration assay and the scratch wound technique, we
showed that DLL4 knockdown leads to significant inhibition of
VEGF-driven endothelial cell migration. Activated Notch4 inhibits
HMEC-1 migration across collagen in response to VEGF and FGF
(46), but not through fibrinogen, by increasing the activity and
affinity of surface-bound h1-integrin (47), whereas overexpression
of HES1 in endothelial cells decreases migration in response to
VEGF or bFGF (45). Thus, again the surprising result is that the
effects of down-regulation of DLL4 are similar to the effects of up-
regulation of Notch signaling.
In summary, we have quantitatively shown for the first time that
the expression of DLL4 is up-regulated in CC-RCCs and that the
reduction of basal DLL4 expression has profound effects on
multiple endothelial functions important in tumor angiogenesis.
Down-regulation of DLL4 produces many phenotypic features
displayed by up-regulation of the Notch pathway. Therefore, we
propose that an optimal window of the DLL4 expression is
essential for tumor angiogenesis. The selective modulation of the
DLL4 expression within human tumors may represent a potential
novel antiangiogenic therapy.
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